Brief: Lipum Reports Positive Interim Results From Phase 1 Study

Lipum AB (publ)

30/01/2024 06:51

Jan 30 (Reuters) - Lipum AB (publ)  LIPUM.ST :
    * REPORTED ON MONDAY POSITIVE INTERIM RESULTS FROM CLINICAL
PHASE
1 STUDY
    * SHOWING THAT SOL-116 REDUCES PLASMA BSSL LEVELS IN HEALTHY
SUBJECTS
    * CONFIRM EXPECTED PHARMACOKINETIC PROFILE, CONSISTENTLY
GOOD
SAFETY PROFILE AND THAT SOL-116 INTERACTS WITH ITS TARGET
PROTEIN BSSL

 Source text for Eikon:  urn:newsml:reuters.com:*:nMFN3G2zsL
 Further company coverage:  LIPUM.ST  

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))